NCT05319093View on ClinicalTrials.gov

Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients

UnknownOBSERVATIONAL

Enrollment

40

Participants

Timeline

Start Date

April 30, 2022

Primary Completion Date

July 31, 2023

Study Completion Date

December 31, 2023

Conditions

FatigueMultiple Sclerosis

Interventions

DRUG

Ozanimod

Three-months, longitudinal observational period

Sponsors

Collaborators (1)

Bristol-Myers Squibb

All Listed Sponsors

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Brigham and Women's Hospital

OTHER

NCT05319093 - Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients | Biotech Hunter | Biotech Hunter